

Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

ENGOT Lead Group: NSGO



n=360+12

Platinum Sensitive Ovarian Cancer in Response

n=180
gBRCA *mut*

n=180
G3 serous
gBRCA *wt*

Niraparib 300 mg daily

Placebo

Niraparib 300 mg daily

Placebo

ENGOT Group	No. of sites	MoH + EC	Site Initiation	Patients consented	Randomised
NSGO (DK, N, SE)	9	Sep-Nov	3	9	3
AGO (Germany)	14	Nov-Dec	Jan		
AGO (Austria)	3	Nov	Nov		
BGOG (Belgium)	5	Nov-Jan	Feb		
GEICO (Spain)	7	Nov-Dec	Jan		
GINECO (France)	7	Nov	Jan		
MaNGO (Italy)	6	Nov-Jan	Feb		
MITO (Italy)	4	Nov-Jan	Feb		
NCRI (UK)	9	Sep-Nov	Feb		
ENGOT TOTAL	64				
US	41	13 May	7	6	3
Canada	7				
Israel, Poland, Hungary	17				
TOTAL	129		10	15	6

